Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis

Neoplasia (United States)

Volumn 19, Issue 2, 2017, Pages 75-83

  Gong, Yongxing ^a   Schumacher, Steven E ^b,c   Wu, Wei H ^a   Tang, Fanying ^d   Beroukhim, Rameen ^b,c   Chan, Timothy A ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARK2 PROTEIN; PROTEIN BCL XL; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; PARKIN; PROTEASOME; PROTEIN BCL X; PROTEIN BINDING; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BCL2L1 GENE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENOME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRION; MOUSE; NONHUMAN; PARK2 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEOPLASM; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 85016060627     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.12.006     Document Type: Article

References (46)

1. [1] Beroukhim, R, Mermel, CH, Porter, D, Wei, G, Raychaudhuri, S, Donovan, J, Barretina, J, Boehm, JS, Dobson, J, Urashima, M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
2. [2] Xiong, D, Wang, Y, Kupert, E, Simpson, C, Pinney, SM, Gaba, CR, Mandal, D, Schwartz, AG, Yang, P, de Andrade, M, et al. A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet 96 (2015), 301–308.
3. [3] Gong, Y, Zack, TI, Morris, LG, Lin, K, Hukkelhoven, E, Raheja, R, Tan, IL, Turcan, S, Veeriah, S, Meng, S, et al. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet 46 (2014), 588–594.
4. [4] Zack, TI, Schumacher, SE, Carter, SL, Cherniack, AD, Saksena, G, Tabak, B, Lawrence, MS, Zhsng, CZ, Wala, J, Mermel, CH, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 45 (2013), 1134–1140.
5. [5] Lucking, CB, Durr, A, Bonifati, V, Vaughan, J, De Michele, G, Gasser, T, Harhangi, BS, Meco, G, Denefle, P, Wood, NW, et al. Association between early-onset Parkinson's disease and mutations in the Parkin gene. N Engl J Med 342 (2000), 1560–1567.
6. [6] Lin, DC, Xu, L, Chen, Y, Yan, H, Hazawa, M, Doan, N, Said, JW, Ding, LW, Liu, LZ, Yang, H, et al. Genomic and functional analysis of the E3 ligase PARK2 in glioma. Cancer Res 75 (2015), 1815–1827.
7. [7] Veeriah, S, Taylor, BS, Meng, S, Fang, F, Yilmaz, E, Vivanco, I, Janakiraman, M, Schultz, N, Hanrahan, AJ, Pao, W, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 42 (2010), 77–82.
8. [8] Shimura, H, Hattori, N, Kubo, S, Mizuno, Y, Asakawa, S, Minoshima, S, Shimizu, N, Iwai, K, Chiba, T, Tanaka, K, et al. Familial Parkinson disease gene product, Parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000), 302–305.
9. [9] Trempe, JF, Sauve, V, Grenier, K, Seirafi, M, Tang, MY, Menade, M, Al-Abdul-Wahid, S, Krett, J, Wong, K, Kozlov, G, et al. Structure of Parkin reveals mechanisms for ubiquitin ligase activation. Science 340 (2013), 1451–1455.
10. [10] Poulogiannis, G, McIntyre, RE, Dimitriadi, M, Apps, JR, Wilson, CH, Ichimura, K, Luo, F, Cantley, LC, Wyllie, AH, Adams, DJ, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 107 (2010), 15145–15150.
11. [11] Zhang, C, Lin, M, Wu, R, Wang, X, Yang, B, Levine, AJ, Hu, W, Feng, Z, Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A 108 (2011), 16259–16264.
12. [12] Norris, KL, Hao, R, Chen, LF, Lai, CH, Kapur, M, Shaughnessy, PJ, Chou, D, Yan, J, Taylor, JP, Engelender, S, et al. Convergence of Parkin, PINK1, and alpha-synuclein on stress-induced mitochondrial morphological remodeling. J Biol Chem 290 (2015), 13862–13874.
13. [13] Wu, W, Xu, H, Wang, Z, Mao, Y, Yuan, L, Luo, W, Cui, Z, Cui, T, Wang, XL, Shen, YH, PINK1-Parkin-mediated mitophagy protects mitochondrial integrity and prevents metabolic stress-induced endothelial injury. PLoS One, 10, 2015, e0132499.
14. [14] Vives-Bauza, C, Zhou, C, Huang, Y, Cui, M, de Vries, RL, Kim, J, May, J, Tocilescu, MA, Liu, W, Ko, HS, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 107 (2010), 378–383.
15. [15] Adams, JM, Cory, S, The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998), 1322–1326.
16. [16] Delbridge, AR, Strasser, A, The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 22 (2015), 1071–1080.
17. [17] Jonas, EA, Porter, GA, Alavian, KN, Bcl-xL in neuroprotection and plasticity. Front Physiol, 5, 2014, 355.
18. [18] Karczmarek-Borowska, B, Filip, A, Wojcierowski, J, Smolen, A, Korobowicz, E, Korszen-Pilecka, I, Zdunek, M, Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 51 (2006), 61–69.
19. [19] Tonon, G, Wong, KK, Maulik, G, Brennan, C, Feng, B, Zhang, Y, Khatry, DB, Protopopov, A, You, MJ, Aguirre, AJ, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102 (2005), 9625–9630.
20. [20] Smith, LT, Mayerson, J, Nowak, NJ, Suster, D, Mohammed, N, Long, S, Auer, H, Jones, S, McKeegan, C, Young, G, et al. 20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer 45 (2006), 957–966.
21. [21] Delbridge, AR, Grabow, S, Bouillet, P, Adams, JM, Strasser, A, Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene 34 (2015), 1872–1876.
22. [22] Kelly, PN, Grabow, S, Delbridge, AR, Strasser, A, Adams, JM, Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 118 (2011), 6380–6386.
23. [23] Kelly, PN, Grabow, S, Delbridge, AR, Adams, JM, Strasser, A, Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. Cell Death Differ 20 (2013), 57–63.
24. [24] Boone, J, Borel Rinkes, IH, van Hillegersberg, R, Robot-assisted thoracolaparoscopic esophagolymphadenectomy for esophageal cancer. Surg Endosc 21 (2007), 2342–2343.
25. [25] Ciriello, G, Cerami, E, Sander, C, Schultz, N, Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22 (2012), 398–406.
26. [26] Nijhawan, D, Zack, TI, Ren, Y, Strickland, MR, Lamothe, R, Schumacher, SE, Tsherniak, A, Besche, HC, Rosenbluh, J, Shehata, S, et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150 (2012), 842–854.
27. [27] Bignell, GR, Greenman, CD, Davies, H, Butler, AP, Edkins, S, Andrews, JM, Buck, G, Chen, L, Beare, D, Latimer, C, et al. Signatures of mutation and selection in the cancer genome. Nature 463 (2010), 893–898.
28. [28] Vogelstein, B, Kinzler, KW, Cancer genes and the pathways they control. Nat Med 10 (2004), 789–799.
29. [29] Wood, LD, Parsons, DW, Jones, S, Lin, J, Sjoblom, T, Leary, RJ, Shen, D, Boca, SM, Barber, T, Ptak, J, et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007), 1108–1113.
30. [30] Hu, HH, Kannengiesser, C, Lesage, S, Andre, J, Mourah, S, Michel, L, Descamps, V, Basset-Seguin, N, Bagot, M, Bensussan, A, et al. PARKIN inactivation links Parkinson's disease to melanoma. J Natl Cancer Inst, 108, 2016.
31. [31] Vander Heiden, MG, Li, XX, Gottleib, E, Hill, RB, Thompson, CB, Colombini, M, Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. J Biol Chem 276 (2001), 19414–19419.
32. [32] Gottlieb, E, Armour, SM, Thompson, CB, Mitochondrial respiratory control is lost during growth factor deprivation. Proc Natl Acad Sci U S A 99 (2002), 12801–12806.
33. [33] Kroemer, G, Reed, JC, Mitochondrial control of cell death. Nat Med 6 (2000), 513–519.
34. [34] Narendra, DP, Jin, SM, Tanaka, A, Suen, DF, Gautier, CA, Shen, J, Cookson, MR, Youle, RJ, PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol, 8, 2010, e1000298.
35. [35] Zhang, C, Lee, S, Peng, Y, Bunker, E, Giaime, E, Shen, J, Zhou, Z, Liu, X, PINK1 triggers autocatalytic activation of Parkin to specify cell fate decisions. Curr Biol 24 (2014), 1854–1865.
36. [36] Lee, K, Lee, MH, Kang, YW, Rhee, KJ, Kim, TU, Kim, YS, Parkin induces apoptotic cell death in TNF-alpha-treated cervical cancer cells. BMB Rep 45 (2012), 526–531.
37. [37] Fujiwara, M, Marusawa, H, Wang, HQ, Iwai, A, Ikeuchi, K, Imai, Y, Kataoka, A, Nukina, N, Takahashi, R, Chiba, T, Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 27 (2008), 6002–6011.
38. [38] Chipuk, JE, Moldoveanu, T, Llambi, F, Parsons, MJ, Green, DR, The BCL-2 family reunion. Mol Cell 37 (2010), 299–310.
39. [39] Willis, SN, Fletcher, JI, Kaufmann, T, van Delft, MF, Chen, L, Czabotar, PE, Ierino, H, Lee, EF, Fairlie, WD, Bouillet, P, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007), 856–859.
40. [40] Arena, G, Gelmetti, V, Torosantucci, L, Vignone, D, Lamorte, G, De Rosa, P, Cilia, E, Jonas, EA, Valente, EM, PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xL and impairing its pro-apoptotic cleavage. Cell Death Differ 20 (2013), 920–930.
41. [41] Chen, D, Gao, F, Li, B, Wang, H, Xu, Y, Zhu, C, Wang, G, Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. J Biol Chem 285 (2010), 38214–38223.
42. [42] Carroll, RG, Hollville, E, Martin, SJ, Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl-1. Cell Rep 9 (2014), 1538–1553.
43. [43] Walensky, LD, BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 13 (2006), 1339–1350.
44. [44] Sasi, N, Hwang, M, Jaboin, J, Csiki, I, Lu, B, Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther 8 (2009), 1421–1429.
45. [45] Hochberg, Y, Benjamini, Y, More powerful procedures for multiple significance testing. Stat Med 9 (1990), 811–818.
46. [46] Magal, SS, Jackman, A, Ish-Shalom, S, Botzer, LE, Gonen, P, Schlegel, R, Sherman, L, Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J Gen Virol 86 (2005), 611–621.